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Introduction 
Over the years, heterocyclic chemistry has gained 
tremendous attention because of its unavoidable 
pharmacological diversity in medicinal chemistry 
research. There has been considerable attention on the 
preparation of useful heterocyclic compounds in orga-
nic synthesis (Ajani and Nwinyi, 2009). These structures 
can either be aromatic or non-aromatic rings (Joule and 
Mills, 2000). Pyrimidine falls under the common azines 
6-membered aromatic nitrogen heterocycles (Eicher and
Hauptmann, 2003), while quinazoline falls under the
category of benzo-fused azines because it resulted from
the fusion of a benzene ring and a pyrimidine atom
(Asif, 2014). Heterocyclic frameworks constitute most of
the active ingredients and building blocks of many
pharmaceuticals, agrochemicals and veterinary pro-
ducts (Ouahrouch et al., 2014; Murgan et al., 2003).
In comparison with our earlier review, quinazoline is 
an heterocycle which belongs to benzodiazine family 
with its heteroatomic nitrogen located at 1- and 3-
positions (Ajani, 2014). Evolution of quinazolines began 
only with discovery of febrifugine, a ‘quinazolinone 
alkaloid”, which was isolated from the Chinese plant 
Aseru (Dichroa febrifuga Lour) and was reported to 
possessing antimalarial potential. It was first synthe-
sized by Gabrial in the year 1903 and was first isolated 
from the Chinese plant aseru (Selvam and Kumar, 
2011).  
Quinazoline is the most commonly experienced hetero-
cyclic core in medicinal research, owing to its wide 
spectrum of pharmacological potential (Luo et al., 2014; 
Selvam et al., 2008) and a huge amount of its 
derivatives are referred to be salient structural synthons 
of numerous physiological relevance and pharma-
ceutical applications (Luo et al., 2014). These include 
usage in drug design and medicinal researches because 
they have been reported to display anti-tobacco mosaic 
virus (anti-TMV), anti-HIV, anti-cancer, antimicrobial, 
antifungal (Patel and Patel, 2011), anti-inflammatory 
(Kumar et al., 2010), anti-hypertensive, antimalarial 
(Werbel and Degnan, 1987) and anti-convulsant (Aly et 
al., 2010) activities among others. 
Furthermore, quinazoline and quinazolinone com-
pounds are also used in the preparation of various 
functional materials for synthetic chemistry and also 
present in various drugs molecule (Rajput and Mishra, 
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 2012). Novel quinazoline-urea analogues were recently 
reported as modulators for Aǃ-induced mitochondrial 
dysfunction making them valuable template in the 
treatment of various neurodegenerative disorders 
(Elkamhawy et al., 2014). Sulfonamides containing 
quinazoline core structure was reported to be suitable 
toolbox for better comprehension of the usefulness of 
bacterial carbonic anhydrases in pathogenesis (Alafeefy 
et al., 2014).  Quinazolinyloxybiaryl urea was identified 
as a new class of inhibitor against SUMO activating 
enzyme 1 which is an excellent oncology target (Kumar 
et al., 2013). Quinazoline core was not left out in the 
new advancement in phenoclustering of diverse model 
systems as an option for the recognition of targeted site 
in drug development (Williams and Hong, 2013). Linear 
and angular 4’,5’-dimethylfuroquinazolines proved to 
intercalate within the DNA double helix, however they 
could not photo-bind DNA bases in the presence of 
ultraviolet radiation (Miolo et al., 2014). Fluorescence 
relays increased sequential identification of Cu2+ and 
CN− through effect of novel quinazoline scaffold (Liu et 
al., 2013; Tang et al., 2013) and their role as turn on 
fluorescence for cysteine and chemodosimeter for NO 
has also been reported (Anand et al., 2014). Some 
quinazoline motifs were shown to display 
bronchodilatory effect at low micromolar 
concentrations on isolated rat trachea, and low toxicity 
both on Balb/c 3T3 mouse fibroblast cells and in mice 
(Špulák et al., 2014). Some valuable quinazoline-based 
compounds include antitumor erlotinib 1, anti-cancer 
iressa 2 and kinase inhibitor lapatinib 3 (Sharma et al., 
2013a; Garofalo et al., 2011) as presented in Figure 1. 
Physical properties  
Quinazoline is a nitrogen-based heterocyclic entity 
which contains a fusion of benzene structure on a 
pyrimidine heterocycle. Hence, it qualifies to be called 
benzopyrimidine. It is a yellow colored solid compound 
having the chemical formular C8H6N2  and a molecular 
mass of 130.1 g/mol. It is usually found in crystalline 
state and it is isomeric with other naphthyridines 
including quinoxaline, phthalazine and cinnoline 
(Selvam et al., 2008). 
Natural occurrence  
Quinazoline occurs mostly as alkaloid in root and 
leaves of some medicinal plants such as Dichroa febrifuga 
(also called Chinese quinine) which belongs to the 
Saxifragaceae family (McLaughlin et al., 2014). They are 
present there as isomeric alkaloids (+)-febrifugine 4a 
and (+)-isofebrifugine 4b. The recent review 
summarized historical isolation information and the 
chemistry studies which culminated in the correct 
structural elucidation of this naturally occurring 
quinazoline-based alkaloid called febrifugine and its 
isomer, isofebrifugine (McLaughlin et al., 2014). 
Hydrachine A 5, a natural quinazoline-core, was 
isolated from the roots of Hydrangea chinensis (Chang et 
al., 2003). The structures of these naturally occurring 
quinazoline motifs are as shown in Figure 2. 
Structure of quinazoline/auinazolinone  
In quinazoline structure, the reactivity behaviour of 
heteroatomic six-membered ring is significantly affec-
ted by the incorporated benzene nucleus. The two N-
heteroatoms are slightly different in their reaction, and 
the existed polarization of the π bond at 3,4-position is 
unveiled in the marked reactions of quinazoline. The 
substituted quinazolines nature is mainly determined 
by position of substituents attachment, i.e. if they are 
either attached to the heteroatomic ring portion or 
benzene nucleus. Another factor has to do with whether 
there is complete conjugation in the pyrimidine ring or 
not (Vijayakumar et al., 2013). 
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Figure 1: Selected commercially available drug bearing quinazoline core 
Figure 2: Structural identity of some naturally occurring quinazoline motifs 
 Classification of quinazolinones 
Based on substitution pattern of its ring system, 
quinazolinones can be classified into the following  
categories: 2-substituted-4(3H)-quinazolinones 6, 3-
substituted one 7, 4-substituted one 8 and 2,3-disubsti-
tuted type 9 (Mhaske and Argade, 2006) as shown in 
Figure 3. Based on the location of oxo group, 
quinazoline could be further categorized into three 
other classes which include: Quinazolin-2(1H)-ones, 
quinazolin-4(3H)-ones and quinazoline-2,4(1H,3H)-
dione (Mahato et al., 2011). It is worthy to note that, of 
all the templates, quinazolin-4(3H)-ones are the 
commonest privileged in terms of naturally occurring 
molecular features or intermediates in numerous 
reported construction route in biosyn-thesis (Mahato et 
al., 2011). 
Justification for expository study on quinazoline 
derivatives  
The recent development in the medicinal importance of 
quinazoline derivatives has necessitated strong interna-
tional effort for the development of new and better 
synthetic strategies for their preparations. The relinqui-
shable attribute of its characteristic offers an effective 
justification for the discovery of these techniques 
(Portela-Cubillo et al., 2009). Synthetic chemists are 
continuously engaging the preparation of quinazoline 
and its derivatives by simple and effective methods 
because of its diverse biological applications such as 
anti-cancer, antiviral and antitubercular agents. The 
quinazoline unit is represented in a number of useful 
natural product scaffolds with laudable activities 
against numerous pharmacological disorders. On this 
note, quinazoline moieties are one of the strongest ever 
reported inhibitors cellular phosphorylation and 
tyrosine kinase. These heterocycles have functioned as 
common ligands in deoxyribonucleic acid, which link to 
adenosine receptors, as well as being efficacious as 
tough antibacterial agents (Portela-Cubillo et al., 2009). 
No wonder their frameworks serve as the foundation in 
the application that have to do with lots of 
pharmaceutical, agrochemical, and veterinary products 
(Portela-Cubillo et al., 2009). The increasing significance 
of quinazolines around therapeutic research has been 
noticed based on the reported highly voluminous 
selling of the quinazoline-based drugs called erlotinib 1, 
which serves a well-recognized curing agent for various 
kinds of   tumours (Fung and Grandis, 2010; Portela-
Cubillo et al., 2009) and prazosin, which serves as a 
blocking agent for R-adrenergic blocker. In the same 
vein, iressa 2, which serves as an inhibitor of EGFR, has 
been certified by the United State Food and Drug 
Administration for the treatment of lung cancer (Portela
-Cubillo et al., 2009). Prozosin, which is another r-
adrenergic blocker, is a popular drug bearing the 
quinazoline unit. Quinazolin-4(3H)-one bearing a 
benzyl functionality at 2-position has been reported to 
have selective inhibitory efficiency on human leucocyte 
elastase as well as on serine protease while 1,3-dimethyl
-1 H-quinazoline-2,4-dione did not only act against 
inflammation but also showed strong and encouraging 
analgesic as well as anticonvulsant potentials (Connolly 
et al., 2005; Maskey et al., 2004). 4(3H)-Quinazoline 
derivatives possess a broad spectrum of biological 
activities and have been identified as antidiabetic and 
CNS depressants (Ding et al., 2004). Due to the 
existence of microorganisms’ resistance phenomenon to 
drugs currently available in the market and consistent 
increase in the outbreak of new diseases, it is highly 
imperative and necessary to continuously design and 
prepare novel heterocyclic scaffolds which display 
improved druggability relevance for medicinal research 
(Ajani, 2014). Therefore, the main goal of this review 
herein is to harness the valuable updated information in 
the medicinal applications and pharmacological 
expertise of quinazoline motifs so as to unfold novel 
routes toward active targets in drug development. 
Synthetic methods 
Quinazoline is relatively easy to prepare and many 
derivatives have been synthesized in order to obtain 
biologically active motifs. Medicinal chemistry 
researchers have designed series of quinazoline 
templates having diverse bioactivities by incorporating 
and attaching several active functionalities to the 
quinazoline core with the aid of improved synthetic 
Figure 3: Classification of quinazoline and quinazolinone derivatives  
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 methodologies (Wang and Gao, 2013). In an earlier 
review, the representative synthetic methods for 
quinazoline moieties, either traditional or novel were 
summarized, and they were classified into five main 
categories which include: Aza-reaction, microwave-
assisted reaction, metal-catalyzed reaction, ultrasound-
promoted reaction and phase-transfer catalysis (Wang 
and Gao, 2013). First quinazoline compound, 2-cyano-
3,4-dihydro-4-oxoquinazoline (Maheswari et al., 2010), 
was prepared in 1869 through the reaction of cyanogens 
with anthranilic acid and later documented by 
Armarego in 1967. 
Biological importance of quinazoline 
Quinazoline and its quinazolinone skeletons are recu-
rrently encountered heterocyclic compounds in thera-
peutic medicine’s literature with wide range of utiliza-
tion including antidiabetic, antileishmanial, antihyper-
tensive, CNS depressant, anticonvulsant, antituber-
cular, anti-HIV, antibacterial, anti-cancer activities 
among others. 
Anti-cancer activity  
Cancer has continued to be topic of great attention in all 
regions of the world due to its global health challenge 
issue to be a leading health problem in developed as 
well as developing countries. It has been consistently 
associated with high mortality rate due to various 
worldwide factors (Antonello et al., 2006). Cancer is an 
abnormal cell growth which is identify through a shift 
in the controlled mechanisms which guides cell 
proliferation and differentiation (Al-Omary et al., 2012). 
Quinazoline bearing sulfonamide functionalities were 
recently recognized as categories of cancer chemothera-
peutics which exhibited noticeable therapeutic poten-
tials on solid tumours (Mohamed et al., 2015). 4-
Anilinoquinazoline bearing sulfonamide at 6-position 
was reported to inhibit the breast cancer cell line 
growth at as low as IC50 = 5.5 μM based on the result of 
investigation of the screening carried out by Yassen et 
al. (2014) whereas when the sulfonamide was on para 
position of the aniline ring there was a reduction in anti
-cancer activity to IC50 = 77.9 μM (Ghorab et al., 2016). 
Quinazolinedione-based redox modulators, 6-((3-acetyl-
phenyl)amino)quinazoline-5,8-dione, was discovered as 
therapy for pancreatic cancer since the oxidative stress 
enhanced through it, catalyzed activation of stress 
kinases (p38/JNK) thereby leading to cancer cell death 
(Pathania et al., 2014). 
EGFR inhibitory activity 
Comprehensive clinical studies showed that inhibiting 
EGFR family receptor TKs represent a major advance in 
the treatment of solid tumor. Gefitinib and erlotinib are 
quinazoline-based compounds which happened to be 
earlier reported salient EGFR inhibitor authorized for 
the curing of diseases related to NSCLC (Wang et al., 
2016). Their mechanism of action was through competi-
tive binding to adenosine triphosphate (ATP)-binding 
pocket of the intracellular EGFR TK site according to 
docking study report; hence, effectively block the 
aberrant EGFR down-stream signaling required during 
tumor survival as well as its proliferation (Wang et al., 
2016; Hynes and Lane, 2005). Owing to this ability, 
structural modifications of earlier discovered gefitinib 
and erlotinib have been achieved to produce more 
effective EGFR inhibitors. For instance, EGFR was 
reported clinically authenticated during rational drug 
design as targeted entity for cancer chemotherapy. In 
addition, various small molecular inhibitors have been 
designed and made available to members of public 
(Zhang et al., 2013a) as quinazoline-based reversible 
inhibitor, e.g. icotinib (Tan et al., 2012) and irreversible 
inhibitors namely; afatinib (Minkovsky and Berezov, 
2008), canertinib and newly reported afatinib derivative 
(Zhang et al., 2013a). According to results of the 
molecular docking study showed in Figure 4, the 
comparison between the binding modes of the 6,7-
dimethoxy-derivative of quinazoline (LASSBio-1814; 
IC50 = 2.4 μM for EGFRwt and 1.02 μM for VEGFR-2) 
and the 6,7-methylenedioxy-derivative of quinazoline 
(LASSBio-1815; IC50 = 34.6 μM for EGFRwt and 26.9 μM 
for VEGFR-2) demonstrated that the structural 
modification performed led to the loss of important 
hydrophobic interaction with Val726, Leu718 and 
Leu792 amino acid residues in EGFRwt binding site; 
and with Val848, Leu840 and Phe918 amino acid 
residues in VEGFR-2 binding site (Barbosa et al., 2014). 
Anti-proliferative activity 
Over the years, it has been established that anti-
proliferative and cyctotoxic drug serve vital functions 
in oncology drug design, either being used in isolation 
or in conjunction with other remedial medical 
procedures which include surgery, radiation and 
pharmacotherapy (Arya et al., 2014; Jabir et al., 2012). 
Arya et al. (2014) reported that novel fluorinated 
benzothiazolo[2,3-b] quinazoline they synthesized via 
greener approach possessed highly promising photo-
anti-proliferative activity upon human keratinocytes 
cell line (Arya et al., 2014) and carcinoma cell line such 
as HL-60 as well as LoVo cell lines (Arya et al., 2014). 
Novel array of isatin-based quinazolines have been 
reported to displayed distinctive selective growth 
inhibitory effect (IC50 = 1.0 ± 0.2 to 2.4 ± 0.4 μM) by 
making use of molecular hybridization technique (Fares 
et al., 2015). 
Anti-tubercular activity 
Tuberculosis (TB) is noted to be one of the oldest and 
most-pervasive diseases in history of mankind (Ankita 
et al., 2014; Yves, 2007). It has been projected that close 
to 1000 million of world population will be newly 
infected, above 150 million individuals will develop 
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 diseases and 36 million will die of TB, between 2002 
and 2020, if adequate preventive and proper control 
measures are not in place (Ankita et al., 2014; Corbett et 
al., 2003). Due to the difficulty in the treatment of drug 
resistant forms of Mycobacterium tuberculosis, the 
development of novel antituberculosis drug entities 
which exhibit new mechanisms of action is urgently 
demanded with the aim of designing more potent 
combination therapy (Mathew et al., 2013). An array of 
new 2-trichloromethyl quinazoline moieties containing 
substituted secondary amine side chain at 4th position 
were designed and investigated via in vitro screening 
for anti-tubercular potential upon M. tuberculosis H37Rv 
ATCC (Srivastav and Shantakumar, 2013) using Alamar 
Blue assay. 8-Methoxy-4-[4-[2-(1-piperidyl)ethoxy]
phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine 
exhibited significant anti-tubercular activity at MIC 
values 50 μM and the in vitro cytotoxicity data using 
THP-1 cells indicated that it was safe as its MIC value 
was much lower than the cytotoxic value as 
documented by Maurya et al. (2013). 
Anti-inflammatory activity 
For the past few decades now, a probable conjunction 
between the application of non-steroidal anti-
inflammatory agents (NSAIDs) and modified cases of 
cancer has continued to exist as special topic that needs 
intense evaluation and research (Chandrika et al., 2008). 
Using NOS-II as biomarker indicator, generally, 
quinazoline motifs are well-known to exhibit significant 
anti-inflammatory properties as inhibitors of NOS-
II (Farag et al., 2013; Tinker et al., 2003), NFKB, TNF-ǂ 
(Serya et al., 2015), IMPDH-II (Rajput and Mishra, 
2012), MAPK, IL-6, PDE-3 and PDE-4 (Serya et al., 
2015). A series of novel 8/10 trifluoromethyl-
substituted-imidazo[1,2-c] quinazolines were 
synthesized and investigated in vivo (rat paw edema) 
for their anti-inflammatory activity and in silico 
(docking studies) to recognize the hypothetical binding 
motif (Rajput and Mishra, 2012; Kumar et al., 2003) with 
the Cycloxygenase enzymes (COX-1 and COX-2) 
employing GOLD (CCDC, 4.0.1 version) software and 
found that compounds (Rajput and Mishra, 2012) 
 
Figure 4: (A) Binding interactions of 6,7-dimethoxy-derivative of quinazoline (yellow) with EGFRwt. (B) Binding interactions of 
methylenedioxy-derivative of quinazoline (gray) with EGFRwt. (C) Binding interactions of 6,7-dimethoxy-derivative of quinazo-
line (yellow) with VEGFR-2. (D) Binding interactions of methylenedioxy-derivative of quinazoline (gray) with VEGFR-2. Docking 
studies were performed with the GOLD 5.1 program. Apolar hydrogen atoms were omitted to improve clarity. The images were 
generated with PyMol Software (Barbosa et al., 2014) 
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 showed good anti-inflammatory activity against 
standard, indomethacin. Quinazoline derivatives are 
also found to show bronco-dilatory properties (Jindal et 
al., 2002). Using tumor necrosis factor-α (TNF-α) as the 
biomedical pathway, ethyl 4-(2-carbamoyl anilino)
quinazoline-2-carboxylate was discovered to be a 
promising anti-inflammatory quinazoline derivative 
with 68% average inhibition on PDE4B enzyme at 
concentration of 10 μM (Serya et al., 2015). 
Antileishmanial activity 
Leishmaniasis, otherwise known as African trypanoso-
miasis or Chagas disease are vector-borne infectious 
diseases whose causative agent are parasites of the 
kinetoplastida order (WHO, 2016; Mendoza-Martínez et 
al., 2015). It is quite alarming to note that approximately 
1.5 million of new cases of cutaneous leishmaniasis 
emerge every year while there is an outbreak of about 
500 000 of new cases of visceral diseases in similar vein. 
Statistics have shown that cutaneous leishmaniasis is 
endemic over 70 countries of the World today (Tiumana 
et al., 2011). Comprehensive review of anti-leishmanial 
drugs discovered for the last decade projected 
quinazoline as highly promising in this regard 
(Sangshetti et al., 2015). A series of quina-zoline-2,4,6-
triamine were synthesized and evaluated in vitro 
against Leishmania mexicana. Among them, N6-
(ferrocenmethyl)quinazolin-2,4,6-triamine showed 
activity on promastigotes and intracellular amastigotes 
as well as low cytotoxicity in mammalian cells 
(Mendoza-Martínez et al., 2015) as shown in Figure 5. 
In the recent review by Sangshetti et al. (2015) about 
anti-leishmanial drug discovery, quinazoline core was 
not left out.  
Antitumor activity 
Literature survey revealed that 4-anilinoquinazoline 
and quinazolinone derivatives are important scaffold 
used in drug design of effective antitumor agents 
(Hassan et al., 2015). Structure-activity relationship 
studies have revealed the significant role of 4-anilino 
substituent in the antitumor diversity of quinazoline 
motifs. From the screening of a series of structurally 
related 4-anilinoquinazoline with N-adamantyl 
formamide in 4-position 10a-f; specifically, compound 
10d (R1 = H; R2 = Cl; R3 = 4-morpholinyl-(CH2)3; R4 = 
CH3), with an IC50 value of 2.06 μM against A431 cells 
with the wild-type EGFR and of 0.009 μM against the 
gefitinib-sensitive cells (Mendoza-Martínez et al., 2015) 
(Figure 6). It displayed efficacy that was about 5-fold 
active than the lead compound to inhibit the growth of 
the cells harboring the EGFR (T790M) mutant (Yu et al., 
2016; Mendoza-Martínez et al., 2015). The synthesis, 
structural elucidation as well as in vitro antitumor 
properties of ruthenium(ii) polypyridyl complexes of 4-
anilinoquinazolines was recently reported (Du et al., 
2016). The reported complexes exhibited substantial 
enhancement in antitumor activity compared to their 
precursor ruthenium polypyridyl moieties. They also 
displayed a dual-targeting manner that can both bind to 
the DNA minor groove and inhibit EGFR (Du et al., 
2016). Caspase-3 activity and cell cycle regulation 
studies revealed that 4-anilinoquinazoline 11 exerted 
antitumor properties with IC50 of 3.4 μM (Palop et al., 
2013). Compared with the parental dasatinib, most of 
the new compounds synthesized by Cai et al. (2013), 
especially 2,4,6-trimethylaniline 12, demonstrated 
significant antitumor activities against six cell lines 
(Figure 7). 
Kinase inhibitory activity 
A series of benzimidazole-based quinazoline 
derivatives were reported to serve as active inhibitor of 
Aurora according to the investigation carried out 
through structure-activity relationship (SAR) and 
quantitative structure-activity relationship (QSAR) 
Figure 5: Molecular docking study N6-(ferrocenmethyl)quinazolin-2,4,6-triamine as anti-leishmanial agent 
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 studies (Sharma et al., 2016). Their noticed activity 
depended on the nature of various substitution patterns 
of the amine which was present in C2 position of this 
heterocycles (Sharma et al., 2016). They were 
established to exhibit improved efficacy as Aurora 
kinase inhibitors, with IC50 values between 0.035 and 
0.532 μM (Sharma et al., 2016). The erythropoietin-
releasing hepatocellular (Eph) receptor tyrosine kinases 
was documented to be of great significance in many 
physiological and pathological actions (Lim et al., 2014). 
Compound 13 provided a potent starting point (IC50 = 
12 nM) for inhibition of Mps1 kinase with 
submicromolar cellular toxicity, reduced MW and 
TPSA, while 14 provided a further boost in biochemical 
potency with IC50 = 2 nM (Bursavich et al., 2013). Thus, 
the comparative study of the two structurally related 
quinazol ine revealed  that  presence of 
methylsulfonamide along the axis of 2-substitutent is 
crucial for enhanced kinase inhibitory activity (Figure 
8). 
Anticonvulsant activity 
Epilepsy is in fact several disorderly phenomena which 
is identified through neuronal hyperexcitability as well 
as neuronal firing. Statistics have shown it to be a 
terrible menace affecting one percentage of global 
population (King et al., 2011; Chen et al., 2007). The 
anticonvulsants used to treat this condition are known 
as antiepileptic drugs and are among the most widely 
used drugs for the treatment of central nervous system 
disorders. New fluorinated quinazolinone motifs have 
been reported as promising anticonvulsant in this 
regard (Zayed, 2014). The outcome of MES and PTZ 
screening carried out on N-(substituted)-1-methyl-2,4-
d i o x o - 1 , 2 - d i h y d r o q u i n a z o l i n e - 3 ( 4 H ) -
carboxamides unveiled them to possess improved and 
better anticonvulsant activity when compared with 
clinical standard drugs which are valproate and 
methaqualone (Deepakumari et al., 2016). 
Methaqualone 15 as a quinazoline analog is an 
important landmark in the field of synthetic 
anticonvulsants (Kashaw et al., 2009). The modification 
of 15 was carried out by El-Azab et al. (2013) to obtain 
quinazolinone scaffold 16 which proved to be 2-fold 
more active than anticonvulsant drug sodium 
valproate. According to the findings of El-Azab and El-
Figure 6: SAR study showing the significant role of 4-anilinoquinazoline as antitumor 
Figure 7: Some quinazoline motifs with antitumor activity 
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 Tahir, (2012), 8-substituted-4(3H)-quinazolinone 17 
demonstrated a better anticonvulsant activity and lower 
toxicity than the reference drugs (Figure 9).  
Antimalarial activity 
Malaria is a well-known parasitic disease in tropical 
regions of the World affecting billons of global 
population today (Birhan et al., 2015; Franklin et al., 
2011). Taking drug resistant challenge into 
consideration, an impressive and violent universal 
attempt is continuously engaged for efficient 
development new antiplasmodial drugs for treatment 
of this well-known illness (Birhan et al., 2015; Olliaro 
and Wells, 2009). Although, the volume of cases and 
mortality rate linked with his illness are reducing 
according to recent update, yet it is the deadliest 
disease known globally (Birhan et al., 2015). The in vivo 
antimalarial activities of the series of quinazolines 
evaluated with the aid of 4 days suppressive standard 
experiment against mice infected with Plasmodium 
berghei  ANKA which were chloroquine-
sensitive isolates revealed that 3-aryl-2-
(substitutedstyryl)-4(3H)-quinazolinones possessed 
improved and enhanced antimalarial properties 
activities having mean suppression of 67.6% (Birhan et 
al., 2015). The mean parasitemia level in mice treated 
with this compound (17.7 ± 0.4) was noticed to have 
been 4 times lesser than that of negative control 
(65.2 ± 0.7) (Birhan et al., 2015). This shoed that the 
targeted compounds have significantly decreased 
parasite load (Birhan et al., 2015). Previous studies 
showed that the presence of amino substituents on 
positions 2 and 4, enhanced the antimalarial potential of 
6-substituted quinazoline (Rojas-Aguirre et al., 2012; 
Jäntschi and Bolboacă, 2006). Hence, this led to the 
strong effect of quinazoline derivative 18 as an 
antimalarial motif on human erythrocytes and on cell 
membrane molecular model (Rojas-Aguirre et al., 2012). 
Likewise, antimalarial activity of quinazoline 19 was 
reported to be by topological and geometrical nature 
and was strongly dependent on partial changes as 
predicted by MDF SAR methodology (Jäntschi and 
Bolboacă, 2006). Nonetheless, for the pyrrolo[3,2-f]
quinazoline 20, acetamido moieties  on positions 2 and 
4 was an essential pharmacophoric framework for 
magical anti-plasmodial potential work in another 
study (Guan et al., 2005; Figure 10).   
HDAC inhibitory activity 
HDACs and histone acetyltransferases (HATs) work in 
contrary to altered chromatin and therefore provide a 
guidance for gene expression (Lin et al., 2016; Pickup et 
al., 2013). HDACs could forcefully suppress the transfer 
of genetic code through existence of chromatin 
condensation with regard to in response to the 
dismissal of acetyl functionality from histone ends (Lin 
et al., 2016; Bolden et al., 2006). A quinazoline-based 
HDAC inhibitor was reported to affect genetically 
expressed routes towards cholesterol biosynthesis via 
mevalonate within prostate cancer cells (Lin et al., 
Figure 8: Some quinazoline motifs with kinase inhibitory activity 
Figure 9: Some quinazoline motifs with anticonvulsant activity  
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 2016). Histone deacetylases (HDAC) play crucial roles 
in numerous biological processes; hence, HDAC 
inhibitory potential of two structurally related 
quinazoline 21 and 22 was compared based on the 
effect of the substituents on the anilino-phenyl at 4-
position of quinazoline. The encouraged activity of 
compound 21 against HDAC (Zhang et al., 2013b) 
concurred with established fact that hydroxamic acid 
commonly exhibit better efficacy as HDAC inhibitor 
than carboxyl-based ones (Zhang et al., 2013b; Kramer, 
2009) while quinazoline 22 with meta-substitution and 
unsaturation near hydroxamic showed even more 
potency with IC50 of 0.2 ± 0.02 μM (Zhang et al., 2013b) 
(Figure 11). 
Anti-HIV activity 
HIV-1 is an etiological agent of AIDS which is universal 
pandemic disease that has led to the death of over 34 
million of the world population (Famiglini and 
Silvestri, 2016). In 2014 alone, AIDS was responsible for 
approximately 1.2 million mortality cases reported 
globally in 2014 (WHO, 2015). Review by Famiglini and 
Silvestri, (2016) exemplified many studies carried out 
on the evaluation of influence of chirality upon 
antiretroviral properties of highly rated HIV-1 NNRTI 
molecules, which include alkenyl substituted 
quinazolinone and nevirapine (Famiglini and Silvestri, 
2016). The chiral segregation, enantiospecific synthesis, 
in addition to biological activity of the HIV-1 NNRTIs 
were fully expatiated (Famiglini and Silvestri, 2016). An 
array of new quinazoline-triazine scaffolds were 
prepared from the reaction of cyanuric halide and 
anthranilic acid via a sequential pathway (Mendoza-
Martínez et al., 2015) and confirmed to possess 
encouraging anti-HIV activity (Modh et al., 2014). A 
series of dihydrobenzo[H]quinazol ine derivatives were 
synthesized by Mohamed et al. (2012) for the purpose 
of anti-HIV examination. They reported that 4-thiophen
-2-ylquinazoline derivative (IC50 = 2.1 μM) emerged as 
the best anti-HIV among the series with therapeutic 
index of 1.9 × 105. Concerning the mechanism of action 
as anti-HIV, these compounds were reverse 
transcriptase inhibitors.  
Phosphodiesterase (PDE) inhibitors 
PDE groups possess numerous variants which are 
commonly special tissue-expression traits, gene 
controlling, enzymatic regulation via phosphorylation 
and regulatory proteins, subcellular localization, as well 
as collaboration with association proteins (Omori and 
Kotera, 2007). Mono-substitution on position 6 of 
quinazoline core was crucial for effective inhibition 
wherein substituents of priority which possessed tight 
package and hydrophobicity are: Methoxy (23b, IC50 = 
0.23 µM), methyl (23c, 0.10 µM), chloro (23d, 0.019 µM), 
thiomethyl (23f, 0.031 µM), and cyano (23p, 0.090 µM) 
functionalities (Takase et al., 1994) as shown in Figure 
12. Administration of 3-substitutedquinazolin-2,4-
dithione as optimized PDE7 inhibitor improved brain 
damage and enhanced behavioral aftermath in a 
permanent middle cerebral artery obstruction 
(pMCAO) stroke model (Redondo et al., 2012; Susín et 
al., 2012). Sánchez et al. (2013) reported the inhibitory 
potencies of quinazoline-4-thione 24 at submicromolar 
levels against the catalytic domain of PDE7. Small-
molecule phosphodiesterase probe investigation 
Figure 10: Some quinazoline motifs with antimalarial activity 
Figure 11: Some quinazoline motifs which served as HDAC inhibitors 
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 established 4-aminoquinazoline 25 as PDE1 inhibitors 
that readily cross the blood brain barrier (Humphrey et 
al., 2014).  
Antihypertensive activity 
Hypertension is well-known to be major community 
health challenge among both middle-aged and older 
population (Deadwania, 2011). The administration of L-
2286 in hypertensive animals has been hypothesized to 
decrease oxidative stress, modulate signaling pathways 
(PI-3K-Akt, MAP kinases) and attenuate NF-κB 
activation, thereby reduces the hypertension-induced 
adverse vascular changes (Magyar et al., 2014). It is well 
established that PARP inhibitors can prevent oxidative 
stress induced tissue damage; they can favorably 
modulate PI-3-kinase/Akt-1 and MAP kinase path-
ways, and inhibit NF-κB activation (Radnai et al., 2012). 
Although, PARP inhibition did not have any anti-
hypertensive effect, it enforces salient safeguarding 
upon process of change of hypertensive heart disorder 
to heart failure in SHRs (Magyar et al., 2014; Bartha et 
al., 2009). A series of novel substituted quinazolin-4(3H)
-one derivatives, with acute LD50>1000 mg/kg, showed 
enhanced bioactivity than standard drug prazosin, 
which plays unique role as anti-hypertensive agent 
through ǂ1 blocking procedure (Pathak et al., 2014). The 
effect of L-2286 on systolic blood pressure (SBP) was 
investigated by Magyar et al. (2014). It was discovered 
that within 32 week of experimental duration, SBP of 
hypertensive (SHR-C, SHR-L) rats was remarkably 
greater as compared with normotensive (WKY) rats 
(Magyar et al., 2014) and the detail of the finding is 
shown in Figure 13. Administering L-2286 was noticed 
to contribute no significant change to SBP of SHR rats 
during the 32 week treatment period (Magyar et al., 
2014).  
Melanin-concentrating hormone receptor 1 antagonists 
Obesity is a chronic universal epidemic disease (Pokin 
et al., 2012) which affects a large number of people 
globally. Over the past 30 years in United States; 60% of 
adults are currently either obese or overweight (Hurt et 
al., 2010). Based on recent National Health and 
Nutrition Examination Survey, it was established that 
great than one-third of the adults (36%) population in 
US are obese due to body mass index (BMI) above 30 
kg/m2 (Högberg et al., 2012). Melanin-concentrating 
hormone (MCH) is a crucial mediator of energy 
Figure 12: Selected quinazoline motifs with notable PDE inhibitory efficiency 
Figure 13: SBP values of normotensive (WKY-C, WKY-L) and hypertensive (SHR-C, SHR-L) rats. Values are means ± SEM. *p<0.05 
(Magyar et al., 2014)  
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 homeostasis (Jeon and Cheon, 2009) which stimulates 
ingested food in mice upon intra cerebro-ventricular 
(icv) injection. Hence, Melanin-concentrating hormone 
receptor 1 (MCHR1) antagonist was reported to be a 
viable option for the treatment of obesity (Högberg et 
al., 2012). Melanin-concentrating hormone receptor 1 
(MCHR1) antagonising quinazoline derivatives were 
authenticated to exhibit remarkable and significant anti-
obesity properties (Sasmal et al., 2012). Pharmacokinetic 
profile showed that oral administration of 30 mg/kg 
b.i.d. of 4-morpholinyl quinazoline led to 12% weight 
reduction within fourteen days in DIOC57BL/6 J mice. 
4-Amino-2-cyclohexyl aminoquinazoline and 4-
dimethylaminoquinazoline were reported to exhibit 
highly promising anti-obesity for suitable weight loss 
programme due to their good affinity for human 
MCHR1 (Kanuma et al., 2005).  
Cathepsin inhibitory activity 
Bischalcones containing 2(1H)-quinazolinones and 2
(1H)-quinazolinethiones analogs were designed and 
evaluated for inhibitory potential (Khan et al., 2015) 
against cathepsin B and cathepsin H (Raghav and 
Singh, 2014). It was found that 26a (X = O) showed 
maximum inhibition at 0.1 nM while the thione analog 
26b (X = S) showed maximum inhibition at 0.05 nM 
which was 2-fold more active than 79 (Raghav and 
Singh, 2014). Among quinazoline derivatives, 2,6-bis(4’-
(dimethylamino)benzylidene)cyclohexanone 27a (X = 
O) was found to exhibit 100% inhibition at 0.1 nM 
which was four times more active than the thione 
counterpart 27b (X = s) with maximum inhibition of 
0.025 nM (Figure 14). 
Antibacterial activity 
Bacterial resistance to existing drugs is a growing 
problem in the world. Considerable researches have 
been performed on the synthesis of new quinazolinone 
derivatives with potent antibacterial activity against the 
Gram +ve bacteria via the way they interact within the 
cell wall and DNA cores (Mohamed et al., 2013). From 
valuable information gathered by a previous review, 
structure activity relationship studies of quinazolinone 
derivatives in various literatures have revealed that 
substitution at positions 2 and 3, existence of halogen 
atom at 6 and 8 positions and substitution (mainly 
amine or substituted amine) at 4th position of the 
quinazolinone ring can improve their antimicrobial 
activities (Jafari et al., 2016). For instance, the primary in 
vitro bioassay at 100 mg/mL against tobacco and 
tomato bacterial wilt revealed 2,3-disubstituted 
quinazolin-4-one 28 (Wang et al., 2014) as strong 
antibacterial agents using turbidimeter test (Wang et al., 
2013) According to the findings of Liu et al. (2014), 4,6-
disubstituted quinazoline metabolite, lapatin B 29 
showed moderate inhibitory activity against aqua-
pathogenic bacteria Vibrio harveyi (Figure 15). 
Antifungal activity 
Three-component design of quinazolinone scaffolds 
bearing 3-acrylamino side chain was evaluated with the 
aid of catalytic amount of CeO2 nanoparticles followed 
by in vitro screening of the targeted quinazolinone for 
antifungal potential upon selected phytopathogenic 
fungi (Zhang et al., 2016). The importance of amide was 
verified and docking study revealed the potential 
antifungal mechanism of action of the quinazolinone 
was via chitinase inhibition (Zhang et al., 2016). Among 
quinazoline examined upon Candida, Aspergillus species 
and Cryptococcus neoformans, most of 5-hydroxy-furo[2,3
-f]quinazolines showed good antifungal activity by 
complete inhibition of the growth of Candida 
Figure 14: Selected bischalcones with cathepsin inhibitory activity 
Figure 15: Selected quinazoline motifs with antibacterial activity 
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 and Aspergillus species when examined at the MIC 
value 12.5 μg/mL (Ryu et al., 2012). In another study, a 
series of benzo[h]thiazolo[2,3-b]quinazolinone designed 
and successfully evaluated for their antifungal activity 
(Gali et al., 2014) while SAR analysis of some tetrazolo
[1,5-c]quinazoline-5-thione derivatives for their inhibi-
tory activity against Candida albicans, show them to be 
very potent at concentration of 100 μg (Antypenko et 
al., 2013).  
Antiviral activity 
Viral diseases threaten latest therapeutic breakthrough 
because of high mutation rates found among viruses, 
which empower them to escape immune systems and 
develop resistance to old existing commercially 
available drugs (Al-Salahi et al., 2016; Jaime et al., 2013). 
Benzoquinazoline compounds have been reported to 
exhibit an interesting antiviral activity which was why 
evaluation of recently prepared 2-thioxo-based benzo[g]
quinazolin-4(3H)-ones was reported against herpes 
simplex and coxsackie virus (Al-Salahi et al., 2016). 
Systematic evaluation of a series of thioquinazoline 
against Tobacco Mosaic Virus (TMV) led to the 
discovery of quinazolin-4-yl based prop-2-en-1-one that 
exhibited encouraging protection properties (EC50 = 
138.1 μg/mL) upon TMV in vivo, which was over three 
times more active than Ribavirin (EC50 = 436.0 μg/mL) 
standard (Wan et al., 2015). A series of quinazoline 
prepared via Schiff bases formation were screened 
against herpes simplex virus-1 (KOS), virus-2 (G) and 
vaccinia virus (Ali et al., 2007), wherein (E)-3-((2-
hydroxybenzylidene) amino)-2-phenyl quinazolin-4
(3H)-one emerged as the most promising antiviral motif 
against the entire tested virus (Kumar et al., 2010). It has 
also been reported that high indicator of the antiviral 
activity of N-methyl-2-((2-oxo-3-phenyl-2H-[1,2,4]tria-
zino[2,3-c]quinazolin-6-yl)thio)acetamide (Kolavenko et 
al., 2013) bearing-adamantane against influenza type A 
H3N2 was due to insertion of carcass amine. 
Anti-oxidant activity 
Reactive oxygen species (ROS) which include 1O2, O2- 
and .OH free radicals and hydrogen H2O2 were 
commonly produced as side products from either 
biochemical interaction or through exogenous factors 
(Sergey et al., 2010). ROS play a vital role as far as aging 
and pathogenetic traits of age responsive diseases are 
concerned (Vagdevi et al., 2012; Manasa et al., 2011). An 
array of quinazoline-2,4-dione Schiff bases were 
reported to possess over 50% inhibitory efficiency upon 
DPPH (IC50 = 25-50 μg/mL) and most of the com-
pounds showed a dose dependent behavior in FRAP 
assay (Vagdevi et al., 2012). 2-Methyl-3-(pyrrolidin-2-
ylidene amino)quinazolin-4(3H)-one was reported to be 
much higher in activity compared with ascorbic acid 
standard (Al-Azawi, 2016). It also served as a powerful 
and highly resourceful scavenger against DPPH and 
Nitric oxide (Al-Azawi, 2016).  
Antidiabetic activity 
Due to widespread nature of diabetes mellitus globally, 
a great deal of effort in applied research is on-going for 
the discovery of new heterocyclic molecules as anti-
diabetic agents with a well detailed information on its 
mode of action (Islam and Loot, 2009; Cheng, 2005). 
Sublethal dosage testing for 1-thioxo-1,2,7,8,9,10-hexa-
hydro-3H-pyrimido[1,6-a]quinazolin-3-one showed that 
it has remarkable potential in (n-STZ) diabetic male as 
antihyperglycemic agent (Ahmed et al., 2012). The (n-
STZ) diabetic male model used in the study acquired 
biological and pathological diagnostic sign related to 
the type 2 diabetes in mankind (Islam and Loot, 2009). 
The one-pot synthesis of a series of quinazolin-4-one in 
the presence of [BMIM+][BF4-] as green and reusable 
catalyst was reported and the attempted investigation 
of antidiabetic activity showed 3-(5-bromopyridin-2-yl)
quinazolin-4(3H)-one to be the most active in this series 
(Dongamanti et al., 2012). 
Antithrombosis activity  
Activated factor X (FXa) is a formidable player in 
thrombin generation through coagulation cascade 
responsibility during the process of atrial fibrillation 
(Bukowska et al., 2013). Activated factor X FXa and 
tachyarrhythmia act synergistically to increase expre-
ssion of protease-activated receptors and inflammatory 
mediators (Bukowska et al., 2013). Some quinazoline 
derivative exerted inhibition of inflammation via this 
route. Elinogrel 30, the structure shown in Figure 16 is a 
marketed available antithrombosis drug containing 
quinazolinone moiety (Nayyar and Arpanarana, 2011). 
Structure-activity relationship study (SAR) 
The SAR study carried out on the selected molecules 
showed that electron-withdrawing and electron-dona-
ting could inform a synthetic chemist about the choice 
of a suitable substitution pattern. Some heterocyclic 
moieties attachments are the basic templates respon-
sible for the regulation of biological activity of targeted 
quinazoline derivative synthesized. From the pain-
staking examination of the SAR, it was collectively 
noted that the positions 2, 4 and 6 are major points of 
biological relevance for improved activities for possible 
drug design (Wang and Gao, 2013). Various 2,4,6-
trisubstituted positions of quinazoline derivatives have 
been evaluated as essential pharmacophoric placement 
for the enhancement of bioactivity (Chandrika et al., 
2009). In addition, the substitution on the pyrimidine 
ring shows more of an antimalarial activity variation of 
a quinazoline derivative (Khan et al., 2014). Triazolo-
fused quinazoline 31 with morpholinyl in 2-position 
and chloro on 6-position was the most potent 
antimicrobial scaffold among the series synthesized by 
Jantova et al, (2005). Presence of electron donating 
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 diamine at 4-position increased the anti-inflammatory 
efficacy of 32 (Lin et al., 2010). Polar functionality like 
hydroxamate when inserted at position-4 of quinazoline 
templates, core was reported to probably provide a 
very active HDACi/HER2i hybrid as seen in 33 which 
was the most potent HDAC inhibitor among the 
quinazolines designed and synthesized by Zhang et al. 
(2013b). Some structural representations of quinazoline 
templates for SAR study are as shown in Figure 17. 
 
Conclusion 
It is reported that in recent times lots of pathogens and 
causative agent of diseases have grown resistant abili-
ties to  the old existing and commercially available 
drugs, which have made the cure of these diseases 
harder and  almost impossible. Quinazoline derivatives 
are considered as important precursors for the synthesis 
of various physiologically significant and pharmaco-
logically utilized molecules. This present article pro-
vides the researchers with a pool of diagnostic infor-
mation in quinazoline templates and thorough under-
standing of their structure activity relationship study in 
order to help mankind against the adverse effect of 
drug-resistance pathogens and newly occurring infec-
tious diseases. This further helps in designing large 
number of quinazoline and quinazolinone compounds 
with a strong impact in curing many fatal disorders and 
infectious diseases. Quinazoline derivatives are there-
fore projected as valuable tools for the development of 
novel pharmacological entities treatment of diverse 
infectious diseases and disorder in the therapeutic 
medicine. 
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